Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. MAKO Surgical's shares outstanding for the quarter that ended in Sep. 2013 was 47.19 Mil.
MAKO Surgical's quarterly shares outstanding
increased
from Jun. 2013 (46.96 Mil) to Sep. 2013 (47.19 Mil).
It means MAKO Surgicalissued new shares from Jun. 2013 to Sep. 2013 .
MAKO Surgical's annual shares outstanding
increased
from Dec. 2011 (42.09 Mil) to Dec. 2012 (46.60 Mil).
It means MAKO Surgicalissued new shares from Dec. 2011 to Dec. 2012 .
MAKO Surgical Shares Outstanding (EOP) Historical Data
The historical data trend for MAKO Surgical's Shares Outstanding (EOP) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of MAKO Surgical's Shares Outstanding (EOP)
For the Medical Devices subindustry, MAKO Surgical's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MAKO Surgical's Shares Outstanding (EOP) Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, MAKO Surgical's Shares Outstanding (EOP) distribution charts can be found below:
* The bar in red indicates where MAKO Surgical's Shares Outstanding (EOP) falls into.
Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.
Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.
A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.
Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.
Be Aware
Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.
Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.
If net earnings is less than 10%, likely to be in a highly competitive business.
MAKO Surgical Shares Outstanding (EOP) Related Terms
Thank you for viewing the detailed overview of MAKO Surgical's Shares Outstanding (EOP) provided by GuruFocus.com. Please click on the following links to see related term pages.
MAKO Surgical Corporation was incorporated in Delaware in November 2004. The Company is a medical device company that markets its advanced robotic arm solution, joint specific applications for the knee and hip, and orthopedic implants for orthopedic procedures. It offers MAKOplasty, an innovative, restorative surgical solution that enables orthopedic surgeons to consistently, reproducibly and precisely treat patient specific, osteoarthritic disease. The Company currently offers MAKOplasty Partial Knee Arthroplasty, or MAKOplasty PKA, and MAKOplasty Total Hip Arthroplasty, or MAKOplasty THA. MAKOplasty PKA, which requires extraction and replacement of the entire joint, enables resurfacing of one or two specific diseased compartments of the joint, preserving significantly more soft tissue and healthy bone of the knee. MAKOplasty procedures are enabled through its proprietary technology consisting of the components which includes its RIO system, its MAKOplasty applications, and its RESTORIS family of implant systems. The centerpiece of MAKOplasty is the RIO system, its proprietary robotic arm, interactive, orthopedic system, that provides both pre-operative and intra-operative guidance to the orthopedic surgeon, enabling tissue sparing bone removal and accurate implant insertion and alignment. The RIO system consists of two elements: a tactile robotic arm utilizing an integrated bone cutting instrument and a patient specific visualization component. The RIO system, version 2.0 of its Tactile Guidance System, or TGS, represents an important expansion from its first generation TGS, enabling and expanding the MAKOplasty PKA application to multicompartmental resurfacing procedures, allowing orthopedic surgeons to treat degenerative knee osteoarthritis from early-stage, unicompartmental degeneration through mid-stage, multicompartmental degeneration with a modular knee implant system, as well as enabling the MAKOplasty THA application. The Company's MAKOplasty PKA application enables surgeons to isolate and resurface just one or two specific diseased compartments of the joint through a minimally invasive incision, preserving significantly more soft tissue and healthy bone of the knee. The MAKOplasty knee resurfacing procedure is performed by the surgeon using the surgical planning and execution software integrated into its patient specific visualization system. The Company's MAKOplasty THA application utilizes the RIO system's tactile, visual and auditory feedback to assist the surgeon in preparing the acetabulum (hip socket) for optimal placement of the acetabular cup implant. The MAKOplasty THA application allows the surgeon to preoperatively plan the placement of the hip implants on a three dimensional image of a pre-operative CT scan. Its RESTORIS family of knee implants is designed to enable minimally invasive restoration of one or two of the diseased compartments of the knee joint. Its RESTORIS family of knee implants for use in si
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FRA:4M6 has been successfully added to your 